Abstract:Glaucoma is a progressive neuropathy characterized by loss of vision as a result of the death of retinal ganglion cells (RGCs). There are currently no effective neuroprotectants to treat this disorder. In this series of studies, we used LINGO-1 antagonists, Nogo-66 receptor (NgR1) antagonists, sNgR-Fc, and brain-derived neurotrophic factor (BDNF) to study the neuroprotection of RGCs in a rat glaucoma model with chronic ocular hypertension. LINGO-1 is a functional member of the NgR1/TROY and the P75 signaling complexes that prevent axonal regeneration by activating RhoA in the central nervous system (CNS). NgR1 mediates the inhibition of axonal regeneration in the presence of three myelin proteins including Nogo-A, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein in the CNS. LINGO-1 was expressed in RGCs and increased after the induction of ocular hypertension. Blocking LINGO-1 function with LINGO-1 soluble protein, LINGO-1-Fc, and LINGO-1 mAb 1A7 significantly promoted RGC survival 2 and 4 weeks after the induction of ocular hypertension and also after optic nerve transection. LINGO-1 formed a receptor complex with TrkB and negatively regulated its activation in the retina after ocular hypertension injury. Blocking LINGO-1 function with LINGO-1-Fc or 1A7 upregulated TrkB phosphorylation after high intraocular pressure injury. BDNF antibody significantly blocked the neuroprotection of LINGO-1-Fc on RGC survival. Similarly, in combination with BDNF, LINGO-1-Fc provided significantly more protection to RGCs in the 4-week glaucoma animals. Thus, LINGO-1 antagonists protect RGCs by regulating the BDNF and TrkB signaling in glaucoma. NgR1 was expressed in RGCs and increased after the induction of ocular hypertension. There was synaptic degeneration of RGCs already detected in the early stage under the elevated intraocular pressure, which preceded cell death in the early stage. The upregulation of Nogo-A may be a possible mechanism of RGC death and synapse degeneration in glaucoma. Soluble (s) NgR-Fc significantly promoted RGC survival at 2 and 4 weeks after ocular hypertension and also after optic nerve transection. Furthermore, sNgR-Fc relieved synaptic degeneration at 5 days, and at 2 and 4 weeks. This suggests that there indeed may be an opportunity to rescue RGCs that are undergoing synaptic alteration, but not yet committed to die. These data suggest that the antagonists of LINGO-1 and NgR1 may provide an attractive therapeutic strategy to prevent the degeneration of RGCs and synapses in glaucoma.

Agonist of growth hormone–releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury

Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.

Ghrelin Attenuates Retinal Neuronal Autophagy And Apoptosis In An Experimental Rat Glaucoma Model

The Effect of A2AReceptor Antagonist on Microglial Activation in Experimental Glaucoma

Towards Retinal Ganglion Cell Regeneration

Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration

Neuroprotection of Retinal Ganglion Cells in Glaucoma by Blocking Lingo-1 Function or Using A Nogo-66 Receptor Antagonist

Cellular senescence mediates retinal ganglion cell survival regulation post‐optic nerve crush injury

Regenerative Effect of Growth Hormone (GH) in the Retina after Kainic Acid Excitotoxic Damage

Advances in Regeneration of Retinal Ganglion Cells and Optic Nerves

Protection of retinal ganglion cells in glaucoma: Current status and future

A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia

Soluble Nogo-66 Receptor Prevents Synaptic Dysfunction And Rescues Retinal Ganglion Cell Loss In Chronic Glaucoma

Intravitreal Injection of Long-Acting Pegylated Granulocyte Colony-Stimulating Factor Provides Neuroprotective Effects via Antioxidant Response in a Rat Model of Traumatic Optic Neuropathy

PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells via different mechanisms after optic nerve injury

Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma

Protection of Pattern Electroretinogram and Retinal Ganglion Cells by Oncostatin M after Optic Nerve Injury

Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury

Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model

Neuro-protection of Retinal Stem Cells Transplantation Combined with Copolymer-1 Immunization in a Rat Model of Glaucoma

Protection of Ciliary Neurotrophic Factor for Retinal Ganglion Cells